Xcout Intel
Vico Therapeutics
Vico Therapeutics is a neurology genetic medicine and biotechnology company pioneering targeted treatments for devastating disorders from its location at the BioScience Park.
Subscribe to see Vico Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vico Therapeutics at a glance
Vico Therapeutics is a biotechnology company headquartered in Netherlands. Its most recent funding round, Series B, raised $70.7M in June 2024. Xcout tracks 1 named person at Vico Therapeutics, including Micah Mackison (Chief Executive Officer).
Vico Therapeutics leadership
- Micah MackisonChief Executive Officer
Vico Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $70.7M | 3 named | |
| Series B | $60M | — | |
| — | $31M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Vico Therapeutics competitors
A few of Vico Therapeutics's closest competitors — see the full list of competitors and alternatives →
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Actio Biosciences is a privately held biotechnology company utilizing genomic medicine to discover and develop treatments for rare diseases and epilepsy.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
ReCode Therapeutics is a clinical-stage genetic medicines company headquartered in Menlo Park, California, and Durham, North Carolina. The company leverages proprietary delivery systems to power a new class of disease-modifying genetic therapies.
Nido Biosciences, Inc. is a clinical-stage holding and biotechnology company headquartered in Watertown, Massachusetts. The company focuses on discovering and advancing treatments for debilitating neurological diseases, including the development of targeted drugs.
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Get Vico Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Vico Therapeutics in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access